Synapse - Robert Motzer

Results (1247)

Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Grüllich, C.; Rini, B. I.; Huseni, M.; Atkins, M.; McDermott, D.; Powles, T.; Escudier, B.; Banchereau, R.; Liu, L. F.; Leng, N.; more...
Oncology Research and Treatment (2019)

Fulltext@MSK | Save

CheckMate 214 patients who discontinued first-line nivolumab + ipilimumab or sunitinib due to treatment-related adverse events

Meeting Abstract

Grünwald, V.; Tannir, N. M.; Motzer, R. J.; Plimack, E. R.; McDermott, D. F.; Barthélémy, P.; Porta, C.; George, S.; Powles, T.; Donskov, F.; more...
Oncology Research and Treatment (2019)

Fulltext@MSK | Save

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Guidelines

Rini, B. I.; Battle, D.; Figlin, R. A.; George, D. J.; Hammers, H.; Hutson, T.; Jonasch, E.; Joseph, R. W.; McDermott, D. F.; Motzer, R. J.; more...
Journal for ImmunoTherapy of Cancer (2019)

Fulltext@MSK | Save

Comprehensive genomic analysis of metastatic non–clear-cell renal cell carcinoma to identify therapeutic targets

Journal Article

Carlo, M. I.; Khan, N.; Zehir, A.; Patil, S.; Ged, Y.; Redzematovic, A.; Coskey, D. T.; Hyman, D. M.; Ladanyi, M.; Chen, Y. B.; more...
JCO Precision Oncology (2019)

Fulltext@MSK | Save

Phase 2 study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis

Meeting Abstract

Lee, C. H.; Shah, A. Y.; Makker, V.; Taylor, M.; Shaffer, D.; Hseih, J. J.; Cohn, A. L.; Di Simone, C.; Marin, A. P.; Rasco, D.; more...
Asia-Pacific Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Motzer, R. J.; Lee, C. H.; Emamekhoo, H.; Matrana, M.; Percent, I.; Hsieh, J. J.; Hussain, A.; Vaishampayan, U. N.; Graham, R.; Liu, S.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis

Meeting Abstract

Lee, C. H.; Shah, A. Y.; Makker, V.; Taylor, M. H.; Shaffer, D.; Hsieh, J. J.; Cohn, A. L.; DiSimone, C.; Pinto Marin, A.; Rasco, D. W.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214

Meeting Abstract

Grünwald, V.; Choueiri, T. K.; Rini, B. I.; Powles, T.; George, S.; Grimm, M. O.; McHenry, M. B.; Maurer, M.; Motzer, R. J.; Hammers, H. J.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)

Meeting Abstract

Choueiri, T. K.; Larkin, J. M. G.; Pal, S. K.; Motzer, R. J.; Venugopal, B.; Alekseev, B. Y.; Miyake, H.; Gravis, G.; Bilen, M. A.; Chudnovsky, A.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis

Meeting Abstract

Uemura, M.; Tomita, Y.; Miyake, H.; Hatakeyama, S.; Kanayama, H. O.; Numakura, K.; Takagi, T.; Kato, T.; Eto, M.; Obara, W.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save